Feature article: Lyme borreliosis prevention: a vaccine is on the way

22. March 2022 by Andreas Pompenig Feature article, Process Expertise

Technical solution for a complicated separation problem in the downstream process

What is Lyme borreliosis?

No vaccine has yet been developed against Lyme borreliosis, a disease transmitted by ticks infected with Borrelia bacteria, which has been spreading dramatically over the past few years. Valneva, a biotech company developing innovative vaccines for infectious diseases, is now working on a new Lyme borreliosis vaccine. ZETA contributed to the production of the valuable active ingredient by providing the perfect technical solution to a complicated separation problem that occurred during the downstream process and thereby plays an important role in bringing an urgently needed vaccine to the market.

How many people get infected?

Lyme disease is the most common vector-borne disease in the northern hemisphere. (Diseases caused by mosquitoes, ticks and fleas that spread pathogens are termed “vector-borne”.) According to the U.S. Center for Disease Control and Prevention (CDC), about 300,000 Americans and 200,000 Europeans contract Lyme disease each year.

The global footprint of the disease is expanding

The global footprint of the disease is expanding; probably due to climate change and warmer winters, ticks are found in places where they have never been observed before. A few decades ago, Lyme was confined to a few small areas, but is now spreading far beyond its usual territory. Particularly in Europe, the number of confirmed cases has been rising steadily over the past 30 years.

Lyme disease vaccine from Valneva.

Lyme disease vaccine from Valneva.
Good news: Valneva is working on a new Lyme disease vaccine.

Good news: Valneva is working on a new Lyme disease vaccine.

The time is ripe for a Lyme disease vaccine

Good news: Valneva is working on a new Lyme disease vaccine.

Close

ZETA Blog

Whitepaper Download

Florian Krainer | Deputy Corporate Head of Project Development
Contact: Florian Krainer
Portfolio Manager Business Line Customised Systems

Our expert is looking forward
to hearing from you!

Related Posts

Review: ZETA Symposium 2024
Feature Article: Production simulation for planning and operation
Feature Article: Virus inactivation with UV light
Event: ACHEMA 2024
Feature Article: How ZETA Drives Innovations
Interview: Thomas Maischberger - Research and Development at ZETA
Close

ZETA Blog

Erhalten Sie interessante Themen aus dem Blog als Newsletter!

The digital assistant from ZETA.
The ZETA
Digital Assistant
  • Last
    search queries
  • Last
    webinars
  • Last
    blog posts
The digital assistant from ZETA.
Your ZETA Digital Assistant

Welcome back!

Recently viewed

No results

You have no results yet.

Maybe also interesting

No results

You have no results yet.